|
SEOUL, South Korea, April 1, 2026 /PRNewswire/ -- Hanon Systems (KS:018880), a leading global automotive thermal management supplier and subsidiary of Hankook & Company Group, today announced the company is supplying its innovative highly integrated cooling entity for electric vehicles.
The very compact and multifunctional thermal management module is designed to integrate several components – including the innovative eCompressor, electronic expansion valve block, a combined water-cooled condenser, and internal heat exchanger, chiller, A/C lines, and pressure and temperature sensors – into a single high power-density solution that reduces system complexity, improves thermal performance, and enhances energy utilization, contributing to extended driving range.
"Our solution transforms thermal management into an efficient and intelligent system," said Soo Il Lee, chief executive officer of Hanon Systems. "By unifying all critical refrigerant thermal management functions into one exceptionally compact module, we achieve savings in both packaging and materials. The company is committed to delivering innovative technologies that shape the future of electric mobility and contribute to a more sustainable future."
The highly integrated cooling entity developed by Hanon Systems was first deployed in BMW's fully electric iX3 SUV model. Designed for electric vehicles, the highly integrated cooling entity manages the thermal needs of multiple vehicle subsystems through an intelligent thermal management module. Weighing only 16 kg (35lbs), the system dynamically regulates refrigerant flow and temperature to optimally support real-time demands such a fast charging, high-performance driving, and extreme weather, all while minimizing energy usage.
In addition, the module includes design elements related to noise, vibration and harshness (NVH), such as vibration isolation components and a sound cover. This design facilitates scalable production and efficient vehicle assembly, supporting adaptability to a wide range of battery electric vehicles platforms.
About Hanon Systems
Hanon Systems, founded in 1986, is a global leader in thermal management solutions. In January 2025, it became a subsidiary of Hankook & Company Group. Its offering includes a wide range of solutions in the areas of heating, ventilation and air conditioning, powertrain cooling, compressor, fluid transport, and electronics and fluid pressure. The company currently operates 50 manufacturing sites and three regional innovation centers and employs more than 20,000 people across 21 countries. To learn more, visit hanonsystems.com.
Follow Hanon Systems:
LinkedIn: https://www.linkedin.com/company/hanonsystems
YouTube: https://www.youtube.com/channel/UC6bSZ7NMg7LPhXDyTOMwebQ/feed
SEOUL, South Korea, April 1, 2026 /PRNewswire/ -- Hanon Systems (KS:018880), a leading global automotive thermal management supplier and subsidiary of Hankook & Company Group, today announced the company is supplying its innovative highly integrated cooling entity for electric vehicles.
The very compact and multifunctional thermal management module is designed to integrate several components – including the innovative eCompressor, electronic expansion valve block, a combined water-cooled condenser, and internal heat exchanger, chiller, A/C lines, and pressure and temperature sensors – into a single high power-density solution that reduces system complexity, improves thermal performance, and enhances energy utilization, contributing to extended driving range.
"Our solution transforms thermal management into an efficient and intelligent system," said Soo Il Lee, chief executive officer of Hanon Systems. "By unifying all critical refrigerant thermal management functions into one exceptionally compact module, we achieve savings in both packaging and materials. The company is committed to delivering innovative technologies that shape the future of electric mobility and contribute to a more sustainable future."
The highly integrated cooling entity developed by Hanon Systems was first deployed in BMW's fully electric iX3 SUV model. Designed for electric vehicles, the highly integrated cooling entity manages the thermal needs of multiple vehicle subsystems through an intelligent thermal management module. Weighing only 16 kg (35lbs), the system dynamically regulates refrigerant flow and temperature to optimally support real-time demands such a fast charging, high-performance driving, and extreme weather, all while minimizing energy usage.
In addition, the module includes design elements related to noise, vibration and harshness (NVH), such as vibration isolation components and a sound cover. This design facilitates scalable production and efficient vehicle assembly, supporting adaptability to a wide range of battery electric vehicles platforms.
About Hanon Systems
Hanon Systems, founded in 1986, is a global leader in thermal management solutions. In January 2025, it became a subsidiary of Hankook & Company Group. Its offering includes a wide range of solutions in the areas of heating, ventilation and air conditioning, powertrain cooling, compressor, fluid transport, and electronics and fluid pressure. The company currently operates 50 manufacturing sites and three regional innovation centers and employs more than 20,000 people across 21 countries. To learn more, visit hanonsystems.com.
Follow Hanon Systems:
LinkedIn: https://www.linkedin.com/company/hanonsystems
YouTube: https://www.youtube.com/channel/UC6bSZ7NMg7LPhXDyTOMwebQ/feed
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Hanon Systems Supplies Highly Integrated Cooling Entity for Electric Vehicles
PRINCETON, N.J. and TOKYO, April 1, 2026 /PRNewswire/ -- NJ Bio, Inc. ("NJ Bio"), a leading provider of integrated drug discovery and development services and Ajinomoto Bio‑Pharma Services ("Aji Bio‑Pharma"), a leading provider of biopharmaceutical manufacturing services and platform technologies, today announced a research collaboration to expand access to AJICAP™, Aji Bio‑Pharma's site‑specific conjugation platform for NJ Bio's discovery‑stage and early development clients. This collaboration broadens NJ Bio's advanced antibody conjugation and linker capabilities, supporting the development of next‑generation antibody–drug conjugates (ADCs) and other targeted therapeutics.
Through the collaboration, NJ Bio will integrate the AJICAP™ platform into its discovery and development workflows, offering clients a robust and highly reproducible approach for site‑specific conjugation of cytotoxic and non‑cytotoxic payloads to antibodies. AJICAP™ enables precise chemical modification at defined lysine residues without the need for antibody engineering, preserving antibody structure and functionality while improving pharmacokinetics, therapeutic index, and overall developability. The platform supports a range of stable, hydrophilic linker systems and is readily incorporated into drug discovery and development programs.
AJICAP™ technology is widely recognized for its scalability, consistency, and compatibility with standard antibody production processes. By integrating this platform, NJ Bio strengthens its position as a comprehensive partner for biopharmaceutical companies seeking end‑to‑end support, from early drug design and discovery through preclinical development.
Clients will benefit from NJ Bio's deep expertise in medicinal chemistry, bioconjugation, and biologics development, combined with the precision, reproducibility, and flexibility of the AJICAP™ platform. Based on prior technical experience working with AJICAP™ technology, NJ Bio anticipates that this collaboration will help reduce development risk, shorten timelines, and improve overall project outcomes.
"Expanding our capabilities with AJICAP™ aligns strongly with NJ Bio's mission to deliver cutting-edge, high-value solutions that accelerate our clients' discovery programs," said Julien Dugal-Tessier, the President and Chief Scientific Officer at NJ Bio. "This collaboration enables us to offer a proven, scalable site-specific conjugation platform, expand access to AJICAP™ capabilities, and support the development of novel antibody-based medicines with improved efficacy and safety profiles."
"AJICAP™ was developed to enable precise and scalable antibody conjugation, and we are excited to extend its reach through this collaboration with NJ Bio," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Dept., Ajinomoto Co., Inc. "Together, we are enhancing the tools available to biopharma innovators to design and develop next-generation targeted therapies for patients."
About NJ Bio, Inc.
NJ Bio, Inc. is a leading Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania and Mumbai, India. The company provides fully integrated chemistry and biology services to biotechnology and pharmaceutical companies, supporting programs from early discovery through GMP manufacturing. With deep expertise in bioconjugation, synthetic organic chemistry, protein‑based biopharmaceuticals, and GMP manufacturing, it specializes in ADCs, targeted protein degraders (TPDs), oligo‑conjugates, and other non‑oncology conjugated therapeutics. The organization delivers customized, science‑driven solutions designed to accelerate development timelines and reduce technical risk. NJ Bio has been recognized as "Best Contract Research Organization (CRO)" for multiple consecutive years at the World ADC Conference. Learn more: https://njbio.com/
About Ajinomoto Bio‑Pharma Services
Ajinomoto Bio‑Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, India, Japan, and the United States, providing support across gene therapy, APIs, and both large‑ and small‑molecule manufacturing. The company offers a broad range of innovative platforms and capabilities—from preclinical and pilot programs through commercial supply—including high‑potency APIs (HPAPI), continuous‑flow manufacturing, oligonucleotide synthesis, biocatalysis, CORYNEX® protein expression technology, and antibody–drug conjugation (ADC) services. Learn more: https://ajibio-pharma.ajinomoto.com
For further information, please contact: HERE
Photo - https://mma.prnasia.com/media2/2947092/Bio_Aji_BioPharma_Services_Collaboration.jpg?p=medium600
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development
